



Personalizing Treatment for **PARKINSON'S DISEASE:**

*What Can You Do to Manage
OFF EPISODES in Your Patients?*

Personalizing Treatment for Parkinson's Disease: What Can You Do to Manage Off Episodes in Your Patients?

FACULTY

Stuart Isaacson, MD

Director

Florida Institute for Neurodegenerative Disorders

Parkinson's Disease and Movement Disorders Center of Boca Raton

Alzheimer's and Memory Disorders Center of South Florida

Associate Professor of Neurology

FIU Herbert Wertheim College of Medicine

Boca Raton, FL

PROGRAM OVERVIEW

This live virtual TeleECHO program will explore the management of off episodes in patients with Parkinson's disease. Interactive case studies presented by expert faculty will evaluate pharmacologic approaches to reduce daily off time, including the efficacy and safety of on-demand therapies. Engaging whiteboard animation will review the pathophysiology of off episodes and the mechanism of action of treatment options.

TARGET AUDIENCE

This educational activity is intended for U.S.-based neurologists and movement disorder specialists involved in the management of patients with PD.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

- Discriminate between the various motor and non-motor "off" phenomena and their underlying developmental mechanisms
- Contrast the distinct mechanisms of action and clinical profiles of therapeutic strategies for treating "off" states
- Develop communication skills that can reveal the presence of "off" episodes

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the long-term treatment and management of patients with PD.

CNE Credits: 1.0 ANCC Contact Hour.

CNE Accreditation Statement: Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

ABIM Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Stuart Isaacson, MD reports that he has received grant/research support from AbbVie, Acadia, Acorda, Adamas, Addex, Allergan, Amaranthus, Amneal, Aptinyx, Axial, Axovant, Benevolent, Biogen, Biohaven, Britannia, Cala, Cerecor, Centogene, Cerevance, Cerevel, Chase Therapeutic, Eli Lilly, Enterin, GE Healthcare, Global Kinetics, Ipsen, Jazz, Kyowa Kirin, Lundbeck, Michael J. Fox Foundation, Neurocrine, Neuroderm, Parkinson Study Group, Pharma2B, Revance, Roche, Sanofi, Sun Pharma, Sunovion, Supernus, Teva, Theravance, and UCB, received honoraria or consultation fees from AbbVie, Acadia, Acorda, Adamas, Addex, Allergan, Amneal, Britannia, Centogene, Cerecor, GE Healthcare, Global Kinetics, Kyowa, Kirin, Lundbeck, Merz, Keifrx, Neurocrine, Neuroderm, Pharma2B, Revance, Sunovion, Supernus, Teva, and UCB, and has participated in speakers bureaus for AbbVie, Acadia, Acorda, Adamas, Allergan, Amneal, GE Healthcare, Kyowa Kirin, Lundbeck, Neurocrine, Sunovion, Supernus, and Teva.

CME Content Review

The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Diana Tommasi, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Daniel Dasilva, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Ashley Whitehurst, Program Manager for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this activity. To receive credit participants must:

1. Read the CME/CNE information and faculty disclosures.
2. Participate in the activity.
3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge,

experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com. Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at <http://medlearninggroup.com/privacy-policy/>

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com



This activity is provided by Med Learning Group



This activity is co-provided by Ultimate Medical Academy/Complete Conference Management (CCM).

This activity is supported by an educational grant from Sunovion

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Personalizing Treatment for **PARKINSON'S DISEASE:**

What Can You Do to Manage OFF EPISODES in Your Patients?



AGENDA

1. Off Episodes in Parkinson's Disease: An Overview

- a. Incidence of off episodes in Parkinson's disease
- b. Motor and non-motor symptoms
- c. Types of off episodes
- d. Impact of off episodes on patient quality of life
- e. Timing of off episodes

2. Management of Off Episodes

- a. Factors affecting PD management
- b. Oral therapies
 - i. Adjusting levodopa dose or administration frequency
 - ii. Switching to an extended-release formulation
- c. Adjunctive therapies
 - i. Efficacy and safety of available options
 - ii. Selecting an appropriate agent
 - iii. Common adverse events with adjunctive therapies
- d. On-demand therapies
 - i. Inhaled levodopa
 - ii. Subcutaneous apomorphine
 - iii. Sublingual apomorphine film
- e. Surgical options for advanced disease

3. Personalizing Treatment

- a. Selecting treatment options based on type of off episode
- b. Considering patient-specific factors
- c. Goals of therapy
- d. Multidisciplinary care of Parkinson's disease

4. Interactive Case Studies

5. Questions and Answers

Personalizing Treatment of Parkinson's Disease: What Can You Do to Manage Off Episodes in Your Patients?

Stuart Isaacson, MD

Director, Florida Institute for Neurodegenerative Disorders
Parkinson's Disease and Movement Disorders Center of Boca Raton
Alzheimer's and Memory Disorders Center of South Florida
Associate Professor of Neurology
FIU Herbert Wertheim College of Medicine
Boca Raton, FL

Disclosures

- **Stuart Isaacson, MD** reports that he has received grant/research support from AbbVie, Acadia, Acorda, Adamas, Addex, Allergan, Amarantus, Amneal, Aptinyx, Axial, Axovant, Benevolent, Biogen, Biohaven, Britannia, Cala, Cerecor, Centogene, Cerevance, Cerevel, Chase Therapeutic, Eli Lilly, Enterin, GE Healthcare, Global Kinetics, Ipsen, Jazz, Kyowa Kirin, Lundbeck, Michael J. Fox Foundation, Neurocrine, Neuroderm, Parkinson Study Group, Pharma2B, Revance, Roche, Sanofi, Sun Pharma, Sunovion, Supernus, Teva, Theravance, and UCB, received honoraria or consultation fees from AbbVie, Acadia, Acorda, Adamas, Addex, Allergan, Amneal, Britannia, Centogene, Cerecor, GE Healthcare, Global Kinetics, Kyowa, Kirin, Lundbeck, Merz, Keifrx, Neurocrine, Neuroderm, Pharma2B, Revance, Sunovion, Supernus, Teva, and UCB, and has participated in speakers bureaus for AbbVie, Acadia, Acorda, Adamas, Allergan, Amneal, GE Healthcare, Kyowa Kirin, Lundbeck, Neurocrine, Sunovion, Supernus, and Teva.
- During this lecture, Dr. Isaacson may mention the use of medications for both FDA-approved and nonapproved indications.

This activity is supported by an educational grant from Sunovion


Learning Objectives

- Discriminate between the various motor and non-motor “off” phenomena and their underlying developmental mechanisms
- Contrast the distinct mechanisms of action and clinical profiles of therapeutic strategies for treating “off” states
- Develop communication skills that can reveal the presence of “off” episodes


Current and Future Prevalence of Parkinson’s Disease

- Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease
- Affects 1% of population over 60 years of age
- Enormous public health challenge

Projected number of individuals over 50 years of age with PD: 2005 through 2030



Projected number of people over age 50 with PD



Dorsey ER, et al. *Neurology*. 2007;68:384-386. National Institute of Neurological Disorders and Stroke (NINDS). Parkinson's disease (www.ninds.nih.gov/Disorders/All-Disorders/Parkinsons-Disease-Challenges-Progress-and-Promise). Parkinson's disease statistics (<https://parkinsonsdisease.net/basics/statistics>). URLs accessed 8/15/2021.

Motor Symptoms Reflect Dopamine Loss


Classic symptom triad in PD

Tremor

Bradykinesia


Rigidity

Loss of postural reflexes



Brooks DP, DePalma D. *Pharmacology*. 1993;47:43-49. Marsden CD. *Clin Neuropharmacol*. 1994;17(suppl 2): S32-S44. Lang AE, Lozano AM. *N Engl J Med*. 1998;339:1044-1053. Nyholm D, Lennernäs H. *Expert Opin Drug Metab Toxicol*. 2008;4:193-203.

Early Treatment Algorithm




MAO-B = monoamine oxidase-B.

Modified from Lyons KE, Pahwa R. *Int J Neurosci*. 2011;121:27-36.

Levodopa Therapy Is Effective Treatment for Parkinson's Disease Throughout Its Course


Effect of PD treatment on development of severe disability



- Rapid symptomatic relief
- Reduces morbidity
- Prolongs survival

Poewe WH, Wenning GK. *Neurology*. 1996;47(suppl 3):S146-S152.

Incidence of Levodopa-Induced Motor Complications



mo(s) = month(s); yr(s) = year(s).

Ahlskog JE, Muenter MD. *Mov Disord*. 2001;16:448-458.

How Do Patients With PD View Their OFF episodes?

Ranking of 10 most troubling symptoms in 173 patients with >6 years disease duration

Rank	Symptom/condition	Total score
1	Fluctuating response to medication	115
2	Mood	96
3	Drooling	85
4	Sleep	83
5	Tremor	67
6	Pain	60
7	Bowel problems	46
8	Urinary problems	40
9	Falls	39
10	Appetite/weight	36

"Voice of the Patient" project (FDA patient meeting, 2016)

"Participants expressed frustration with periods of 'off-time', which was described as **unpredictable exacerbation of symptoms** during which medications were less effective.

A few described the unpredictability that off-time brought into their lives on a daily basis."

FDA = US Food and Drug Administration.

Politis M, et al. *Mov Disord.* 2010;25:1646-1651. FDA. The voice of the patient (www.fda.gov/media/124392/download). Accessed 8/12/2021

Impact of Different Types of OFF Episodes on Quality of Life

Impact of motor complications, especially levodopa-induced dyskinesias, on QoL was studied in 143 patients with PD

- Mobility, ADL, stigma, and communication most strongly affected
- Significant PDQ-39 Summary Index worsened in all 143 patients with PD

Dimensions of PDQ-39 Significantly Related to Motor Fluctuations					
PDQ-39 dimension	End-of-dose fluctuations	Nocturnal akinesia	Early morning akinesia	Unpredictable OFF episodes	Paradoxical Fluctuations
Mobility	✓	✓	✓	✓	✓
ADL	✓	✓	✓	✓	✓
Emotional well-being		✓			
Stigma	✓	✓	✓	✓	✓
Social support		✓			
Cognition		✓			
Communication	✓	✓	✓	✓	✓
Bodily discomfort		✓		✓	
Total score	✓	✓	✓	✓	✓

✓ = Statistically significant; QoL = quality of life; PDQ = Parkinson's Disease Questionnaire; ADL = activities of daily living.

Chapuis S, et al. *Mov Disord.* 2005;20:224-230.

[Click here for whiteboard animation](#)

How Patients Experience the 4 Types of Off Episodes

Motor Fluctuations Reflect Different Types of OFF Episodes


- Types of motor fluctuations^{1,2}
 - “End-of-dose wearing off”—predictable
 - “Delayed time to ON”
 - Delayed-ON (postprandial akinesia)
 - Suboptimal-ON
 - No ON (dose failure)
 - “ON–OFF” phenomena—unpredictable
 - Nocturnal akinesia
 - Early morning akinesia
- Dyskinesias¹ and nonmotor fluctuations^{2,3} may also occur

Relative incidence of different motor fluctuations and dyskinesias ¹		
	Patients (n)	%
Fluctuations	94	66.0
Early morning akinesia	55	58.5
Nocturnal akinesia	54	57.5
End-of-dose fluctuations	74	78.7
Paradoxical fluctuations	47	50.0
“Unpredictable OFFS”	34	36.2
LID	81	57.0
Peak dose	59	72.8
Diphasic	14	17.3
OFF	10	12.4
Morning dystonia	27	33.3

LID = levodopa-induced dyskinesia; MF = motor fluctuation.

1. Chapuis S, et al. *Mov Disord.* 2005;20:224-230. 2. Stocchi F. *Parkinsonism Relat Disord.* 2009;15(suppl 1):S9-15. 3. Martinez-Martin P, et al. *Mov Disord.* 2007;22:1623-1629

OFF Episodes Can Be Predictable or Unexpected: Each Day May Have A Different Pattern




DDCI = dopa decarboxylase inhibitor; WO = wearing off.

Adapted from: Stocchi F. *Parkinsonism Relat Disord.* 2009;15(suppl 1):S9-15.


What Causes OFF Episodes?

- Central mechanisms^{1,2}
 - Progressive neurodegeneration causes striatal denervation leading to reduced presynaptic dopamine storage capacity
 - Long-term “pulsatile” delivery results in postsynaptic changes in striatal pathways
- Peripheral mechanisms³
 - Variability in GI absorption due to:
 - GI dysmotility and delayed gastric emptying secondary to PD and medications
 - Impaired absorption of levodopa transport across the gut-blood barrier
 - Short plasma half-life
 - Variability in blood-brain barrier transport

Change in LD response over time⁴



Plasma concentrations after oral levodopa/carbidopa (25/100)⁵




GI = gastrointestinal; LD = levodopa; 25/100 = 25 mg/100 mg.

1. Calabresi P, et al. *Nat Neurosci.* 2014;17:1022-1030. 2. Olanow CW, et al. *Lancet Neurol.* 2006;5:677-687. 3. Nyholm D, Lennernäs H. *Expert Opin Drug Metab Toxicol.* 2008;4:193-203. 4. Schapira AH, et al. *Eur J Neurol.* 2009;16:982-989. 5. Lipp MM, et al. *Sci Transl Med.* 2016;8:360ra136.


Absorption of Oral Levodopa Is Often Variable

- PD is associated with delayed gastric emptying
- Food can interfere with levodopa absorption
 - High-fat meals can slow gastric emptying
 - Amino acids from food proteins compete with levodopa for absorption
- *Helicobacter pylori* gastric infection can affect levodopa absorption
- Gut bacterial tyrosine decarboxylase can reduce levodopa absorption



Pfeiffer RF, et al *Parkinsonism Relat Disord.* 2020;76:63-71. Stacher G, et al. *Dig Dis Sci.* 1991;36:1259-1265. van Kessel SP, et al. *Nat Commun.* 2019;10:310.

Once OFF Episodes Emerge, Shared Clinical Decision-Making Can Help Guide Adjustment to Levodopa Regimen and/or Addition of Adjunctive Therapy



COMT = catechol-O-methyltransferase; LCIG = levodopa-carbidopa intestinal gel; IR = immediate release.

Vijjaratnam N, Foltynie T. *Drugs.* 2020;80:775-796. Tanner CM. *Am J Manag Care.* 2020;26(12 suppl):S255-S264.

Medication Approaches to Reduce Daily OFF Time

- Carbidopa/levodopa
 - Increase levodopa during day or increase dosing frequency
 - Switch to sustained-release levodopa
 - Switch to ER capsules
 - Levodopa infusion
- Add dopamine agonists
 - Pramipexole
 - Pramipexole ER
 - Ropinirole
 - Ropinirole ER
 - Rotigotine transdermal
- Add MAO-B inhibitors
 - Rasagiline
 - Selegiline
 - Selegiline ODT (Zydis)
 - Safinamide
- Add COMT inhibitors
 - Entacapone
 - Opicapone
 - Tolcapone
- Add amantadine ER capsules at bedtime
- Add adenosine A2A antagonist
 - Istradefylline

ER = extended release; ODT = oral disintegrating tablet; A2A = adenosine A(2A) receptor.

Fox SH, et al. *Mov Disord.* 2018;33:1248-1266. Vijjaratnam N, Foltynie T. *Drugs.* 2020;80:775-796. Tanner CM. *Am J Manag Care.* 2020;26(12 suppl):S255-S264.

Factors Affecting PD Management

- Symptoms and symptom severity
- Occupational status and lifestyle
- Age
- Non-motor symptoms
 - Cognitive, behavioral, and psychiatric status
 - Sleep disorders (RBD, sleep apnea)
 - Orthostatic hypotension
 - Constipation
- Comorbidities and concomitant medications

RBD = REM (rapid eye movement) sleep behavior disorder.

Treatment Options

Available levodopa/ carbidopa formulations

CD/LD IR

- 25/100 IR
- 25/100 ODT
- 25/250 IR
- 10/100 IR

CD/LD ER

- 25/100 CR
- 50/200 CR
- 95 ER
- 145 ER
- 195 ER
- 245 ER

COMT inhibitors can also prolong plasma levodopa

COMT inhibitors

- Tolcapone
- Entacapone
- Opicapone


Combination

- CD/LD/EC

Additional therapies in development include longer ER formulations, continuous subcutaneous infusions, and gene therapies

CD = carbidopa; EC = entacapone.

Strategies to Increase Plasma Levodopa Include Higher Dose, More Frequent Timing, ER Formulations, and Inhibition of COMT



CR = controlled/sustained release.


1. Hsu A, et al. *J Clin Pharmacol*. 2015;55:995-1003. 2. Nyholm D, et al. *AAPS J*. 2013;15:316-323. 3. Hauser RA, et al. *Neuropsychiatr Dis Treat*. 2018;14:839-842.

COMT Inhibitors

- Prevent peripheral degradation of levodopa by inhibiting COMT
- Prolong duration of levodopa benefit
- Potentially reduce levodopa dose necessary for a clinical benefit

Available options include:

- Tolcapone
- Entacapone
- Opicapone



*Not significant. † $P < .01$.

d = day.

Rinne UK, et al. *Neurology*. 1998;51:1309-1314. Parkinson study group. *Ann Neurol*. 1997;42:747-755. Brooks DJ, et al. *J Neurol Neurosurg Psychiatry*. 2003;74:1071-1079. Poewe WH, et al. *Acta Neurol Scand*. 2002;105:245-255. Lees AJ, et al. *JAMA Neurol*. 2017;74:197-206 and supplement.

Additional Treatment Options

Striatal dopaminergic tone can be increased by MAO inhibitor or dopamine agonist

- MAO-B inhibitors
 - Selegiline
 - Selegiline ODT
 - Rasagiline
 - Safinamide
- Dopamine agonists
 - Pramipexole
 - Pramipexole ER
 - Ropinirole
 - Ropinirole ER
 - Rotigotine

Nondopaminergic adenosine and glutamate antagonists can also modulate striatal pathways


- NMDA antagonists
 - Amantadine IR
 - Amantadine ER
 - Amantadine ER hs
- Adenosine A2A antagonist
 - Istradefylline

NMDA = N-methyl-D-aspartate; hs = at bedtime.

Controlled-Release Dopamine Agonists

Available options include:



- Ropinirole
- Pramipexole
- Rotigotine



*Measured in early morning in RECOVERY but at any time of day during open-label extension; †P= .0135 (pramipexole ER vs PBO at week 33); ‡P< .005.

M = month; EoM = end of month; LOCF = last observation carried forward; SE = standard error; UPDRS = Unified Parkinson's Disease Rating Scale; XL = extended release; BL = baseline; PBO = placebo; hr(s) = hour(s).

1. Poewe W, et al. *Neurology*. 2011;77:758-766. 2. Trenkwalder C, et al. *Basal Ganglia*. 2012;2:79-85. 3. Pahwa R, et al. *Neurology*. 2007;68:1108-1115.




Safinamide

- Safinamide is an α -aminoamide
- Mechanism of action
 - Both dopaminergic and nondopaminergic
 - Inhibition of MAO-B
 - Na⁺ channel blockade
 - Modulation of stimulated release of glutamate
- Oral: 50 or 100 mg once in 1 day

Müller T. *Clin Pharmacol*. 2018;10:31-41.

Extended-Release Amantadine


Diary summaries from patients with PD



Pahwa R, et al. *JAMA Neurol.* 2017;74:941-949.

Istradefylline—Once Daily

OFF time reduction ~1 hour



Adenosine A2a receptors

- Enriched in basal ganglia
- Regulate indirect pathways
- Activation reduces motor activity
 - In contrast, dopamine increases motor activity

Decreased OFF time and increased ON time without troublesome dyskinesia at 12 weeks

Increase in ON time without troublesome dyskinesia with istradefylline: 0.55-0.96 hrs/d across 4 clinical trials

*Nominal *P*-values: *P*= .026 in study 1 (40 mg); *P*= .135 in study 2 (20 mg); *P*= .085 (20 mg) and *P*= .048 (40 mg) in study 3; *P*= .008 for both 20 mg and 40 mg in study 4.

Istradefylline (Nourianz®) prescribing information (PI), 2020 (www.nourianz.com/assets/pdf/nourianz-full-prescribing-information.pdf) package insert]. Accessed 8/12/2021. Kalia LV, et al. *Mov Disord.* 2013;28:131-144. Mishina M, et al. *PLoS One.* 2011;6:e17338. Saki M, et al. *Naunyn-Schmiedeberg Arch Pharmacol.* 2013;386:963-972. Varani K, et al. *FASEB J.* 2010;24:587-598.

Reduction in OFF Time With Adjunctive Therapies

Medication	OFF-time reduction	Doses per day, no.
Dopamine agonists		
Pramipexole/ropinirole	1.5–2 hours/day	3
Pramipexole ER/ropinirole XL/rotigotine	0.7–1.5 hours/day	1
MAO-B inhibitors		
Rasagiline/safinamide/selegiline ODT	0.9–1.6 hours/day	1
COMT inhibitors		
Entacapone/opicapone	0.7–1.2 hours/day	0 (combination) –1
A2A antagonists		
Istradefylline	1 hour/day	1
NMDA antagonist		
Amantadine ER	1 hour/day	1

Pahwa R, et al. *Neurology*. 2006;66:983-995. Schapira AH, et al. *Neurology*. 2011;77:767-764. Pahwa R, et al. *Neurology*. 2007;68:1108-1115. LeWitt PA, et al. *Neurology*. 2007;68:1262-1267. Pramipexole (Mirapex®) PI, 2021 (<https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Mirapex/Mirapex.pdf>). Ropinirole PI, 2020. Pramipexole ER (Mirapex® ER) PI, 2018 (www.accessdata.fda.gov/drugsatfda_docs/label/2018/022421s017bl.pdf). Ropinirole extended release (Requip® XL) PI, 2017 (www.accessdata.fda.gov/drugsatfda_docs/label/2017/022008s009bl.pdf). Rotigotine transdermal system (Neupro®). Rasagiline (Azilect®) PI, 2020 (www.azilect.com/azilect.pdf). Selegiline orally disintegrating (Zelapar®) PI, 2021 (www.bauschhealth.com/Portals/25/Pdf/PI/Zelapar-PI.pdf). Entacapone PI, 2015 (www.ajantapharmausa.com/pdf/Entacapone_Tablets_Single_Package_Insert.pdf). Opicapone (Ongentys®) PI, 2020 (www.neurocrine.com/assets/ONGENTYS-PI.pdf). Istradefylline (Nourianz®) PI, 2020 (www.nourianz.com/assets/pdf/nourianz-full-prescribing-information.pdf). Amantadine (Gocovri) PI, 2021 (www.gocovrihcp.com/pdf/Gocovri_Prescribing_Information.pdf). URLs accessed 8/13/2021.

Common Dopaminergic Adverse Events in Advanced PD

	Dizziness	Hallucinations	Nausea	Orthostatic Hypotension	Somnolence	Dyskinesia
Carbidopa/levodopa	2–3%	3–5%	4–6%	1%	NR	13–16%
MAO-B inhibitors	2–14%	<3–6%	6–20%	2–9%	2–6%	18–21%
Dopamine agonists	2–26%	7–17%	11–30%	1–53%	7–32%	13–47%
Apomorphine SC	20%	10%	30%	20%	35%	35%
Entacapone	8%	4%	14%	4%	2%	25%
Istradefylline	6%	6%	6%	NR	NR	17%
Amantadine ER	16%	21%	8%	13%	<3%	NR

PI does not list frequency of AEs; taken from ELLDOPA, CALM-PD, and 056.

SC = subcutaneous.

Apomorphine injection (Apokyn®) PI, 2020 (www.apokyn.com/sites/all/themes/apokyn/content/resources/apokyn_pi.pdf). Entacapone (Comtan®) PI, 2020 (<https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b1aceb59-9be8-43b8-83d6-81e05e4b51e4>) (www.accessdata.fda.gov/drugsatfda_docs/label/2010/020796s1s1bl.pdf). Istradefylline (Nourianz®) PI, 2020 (www.nourianzhcp.com/assets/pdf/nourianz-full-prescribing-information.pdf). Amantadine extended-release (Gocovri®) PI (www.gocovrihcp.com/pdf/Gocovri_Prescribing_Information.pdf). URLs accessed 8/12/2021.

Delayed ON, Morning OFF, and Dose Failures


- Variability of intestinal levodopa absorption can be addressed with non-GI, on-demand formulations of levodopa and apomorphine
- GI (all affected by GI dysmotility)
 - Oral CD/LD
 - Orally disintegrating CD/LD tablet
 - Liquid CD/LD
- Non-GI (avoids GI variability)
 - Apomorphine sublingual
 - Apomorphine subcutaneous injection
 - Inhaled LD

Pfeiffer RF, et al. *Parkinsonism Relat Disord.* 2020;76:63-71.


Plasma Levodopa Concentrations Variable After Oral CD/LD in PD

Oral CD/LD 25/100

Fasted: no food at least 1 hour before and 1 hour after dose¹




After meal: 4–5 hours after morning CD/LD, patients ate meal then dose²



1. Lipp MM, et al. *Sci Transl Med.* 2016;8:360ra136. 2. Safirstein BE, et al. *Clin Ther.* 2020;42:1034-1046.

Once OFF Episodes Emerge, Shared Clinical Decision-Making Can Help Guide Adjustment to Levodopa Regimen and/or Addition of Adjunctive Therapy



Vijjaratnam N, Foltynie T. *Drugs*. 2020;80:775-796. Tanner CM. *Am J Manag Care*. 2020;26(12 suppl):S255-S264.

[Click here for whiteboard animation](#)

Mechanism of Action of Therapies for Off Episodes

On-Demand Therapies Are Efficacious and Generally Well Tolerated for Management of “OFF” Episodes

Drug	Efficacy	Most common adverse events
Sublingual apomorphine	<ul style="list-style-type: none"> • Significant improvement in UPDRS-III scores vs PBO (LSM treatment difference: -7.6 at 30 min after dosing at week 12) • 35% of apomorphine patients turned ON 30 min post dose vs 16% on PBO 	<ul style="list-style-type: none"> • Nausea (treat with antiemetic beginning 3 days prior to 1st dose) • Oral/pharyngeal soft tissue swelling • Oral/pharyngeal soft tissue pain and paresthesia • Dizziness • Somnolence
Subcutaneous apomorphine	<ul style="list-style-type: none"> • Significant improvement in UPDRS-III scores vs placebo (-23.9 vs -0.1) • Significant efficacy as recorded by Columbia Parkinson's disease score 	<ul style="list-style-type: none"> • Nausea and/or vomiting • Dyskinesia • Dizziness/ postural hypotension • Rhinorrhea • Somnolence/drowsiness • Yawning • Hallucination/confusion • Edema/swelling of extremities
Inhaled levodopa	<ul style="list-style-type: none"> • Significant improvement in UPDRS-III scores vs PBO (LSM treatment difference: -3.07 at 30 min after dosing at week 12 (84 mg)) • 58% of inhaled levodopa 84 mg patients turned ON by 60 min post dose vs 36% on PBO 	<ul style="list-style-type: none"> • Cough • Upper respiratory tract infection • Sputum discolored

LSM = least squares mean.

Hauser RA, et al. *Postgrad Med.* 2021;Jun 30: Epub ahead of print.

Levodopa Inhalation Powder

- Levodopa inhalation powder is a self-administered, LD inhalation powder for treatment of OFF periods in people with PD as an adjunct to oral CD/LD regimen¹
- Drug/device combination consists of an LD powder formulation in capsules that are placed in a breath-actuated inhaler that delivers dose
 - Absorbed in lower lung, thereby bypassing GI system and avoiding first-pass metabolism¹⁻³
- 84-mg dose consists of two 42 mg capsules; may be taken a maximum 5 times/day³




1. LeWitt PA, et al. *Mov Disord.* 2016;31:1356-1365. 2. Lipp MM, et al. *Sci Transl Med.* 2016;8:360ra136. 3. LD inhalation powder (Inbrija) PI, 2020 (www.inbrija.com/prescribing-information.pdf). Accessed 8/12/2021.

Inhaled Levodopa Reaches Mean Peak Plasma Concentrations Faster Than Oral Carbidopa/Levodopa

Single-dose PK study in 23 PD patients following high-fat, high-protein meal*

Increase in mean plasma LD levels within 5 minutes after inhalation



Median T_{max} 15 minutes as compared to 120 minutes for oral CD/LD




*4–5 hours after morning CD/LD, patients ate meal, then received study drug; †Inhaled LD 84 mg co-administered with 25 mg oral CD for true PK comparison of LD. PK = pharmacokinetic; SD = standard deviation.

Modified from Safirstein BE, et al. *Clin Ther.* 2020;42:1034-1046.

Orally Inhaled Levodopa




UPDRS Part III motor score change from 0–60 min post-dose at week 12²




1. Safirstein BE, et al. *Clin Ther.* 2020;42:1034-1046. 2. Modified from LeWitt PA, et al. *Lancet Neurol.* 2019;18:145-154.

Apomorphine Subcutaneous Injection

- Apomorphine, “old” drug, used since 1869 as emetic
- Potent dopamine agonist at both D1 and D2 dopamine-receptor sites
- Administered subcutaneously with ~100% bioavailability
 - Fast-acting (T_{\max} = 10–60 min)
 - Short duration (half life = 30–60 min)
- Consistent efficacy similar to levodopa



Rapid, reliable improvement after apomorphine injection (APO302 study)




Mean change in UPDRS motor scores did not differ between APO vs APO+2 treatment groups

APO = apomorphine; APO+2 = APO at typically effective dose + 0.2 mL; T_{\max} = time to maximum plasma concentration, min = minute(s).

Apomorphine subcutaneous injection (Akpyn) PI, 2020 (www.apokynhcp.com/sites/all/themes/apokyn/content/resources/apokyn_pi.pdf). Accessed 8/12/2021. Pfeiffer RF, et al. *Parkinsonism Relat Disord.* 2007;13:93-100.

Study APO-303: Robust, Rapid, Reliable

Change in UPDRS motor score with SC APO



Pahwa R, et al. *J Neural Sci.* 2007;258:137-143.

Delayed-ON of Initial Morning Dose (Morning OFF)


- Common in PD
 - EUROPAR study: 59.7% of patients¹
 - Japanese study: patient-reported prevalence of 79.8%, with 37.8% reporting EMO every day²
- Cause of impaired mobility until onset of effect
- Significantly reduces patients' quality of life^{2,3}
- Significantly increases caregiver burden²

EMO = early morning OFF.

1. Rizos A, et al. *Parkinsonism Relat Disord.* 2014;20:1231-1235. 2. Onozawa R, et al. *J Neurol Sci.* 2016;364:1-5. 3. Chapuis S, et al. *Mov Disord.* 2005;20:224-230.

Early Morning OFF (EMO) Periods Prevalent Throughout Course of PD

- EMO periods experienced by 59.7% of PD patients
- EMO prevalent across all stages of the disease with a higher proportion in moderate disease ($P < .01$)



EUROPAR study


- European observational study
- 320 Parkinson's patients receiving dopaminergic treatment
- EMO periods identified by structured questionnaires (UPDRS-35 and PDSS-14)

PDSS = PD sleep scale; H&Y = Hoehn and Yahr (scale).

Rizos A, et al. *Parkinsonism Relat Disord.* 2014;20:1231-1235.

At least 50% of PD Patients Experienced EMOs Despite Rotigotine Patch or Prolonged-Release DAs

Patients experiencing EMOs despite treatment (EUROPAR study)




DA = dopamine agonist.

Modified from Rizos A, et al. *Parkinsonism Relat Disord.* 2014;20:1231-1235.

First Oral Levodopa Dose Is Delayed In Morning Akinesia, Probably Due to Gastroparesis

Pharmacokinetic curve after single dose of levodopa*




- Pharmacokinetics of levodopa assessed in 19 patients with advanced PD with and without delayed onset of first levodopa dose in morning
- Difference in plasma concentrations in two groups likely due to delayed gastric emptying

*Data are shown as mean (SD); † $P < .05$.

Chaná P, et al. *J Neurol Neurosurg Psychiatry.* 2004;75:1782-1783.

AM-IMPAKT


Apomorphine produced more reliable ON than levodopa



Modified from Isaacson S, et al. *Mov Disord Clin Pract.* 2017;4:78-83.

Sublingual Apomorphine


- A sublingual formulation of apomorphine was approved in May 2020, for use as rescue medication in overcoming OFF periods
- Thin-film strip containing apomorphine in bilayer (to avoid oral irritation)
- Patients are instructed to keep film under their tongue for drug to be absorbed through oral cavity
- Initial study showed OFF reversal within 30 minutes
 - ON mean duration of 50 minutes
 - No major AEs, including oral mucosal irritation
 - Rapid delivery



Apomorphine sublingual film (Kynmobi™) PI, 2020 (www.kynmobi.com/Kynmobi-Prescribing-Information.pdf). Accessed 8/12/2021. Hauser RA, et al. *Mov Disord.* 2016;31:1366-1372.

Sublingual Apomorphine Efficacy

Change from pre-dose in UPDRS Part III motor examination score at week 12 (mITT population)




Change from pre-dose to 30 min post-dose for UPDRS part III score at 12 weeks was -11.1 (SE 1.5) and -3.5 (SE 1.3) for APL and PBO groups, respectively (mean difference = -7.6 ; $P = .0002$).

* $P < .05$; † $P < .001$; ‡ $P < .0001$.

APL = apomorphine sublingual film; mITT = modified intent-to-treat.

Full ON response at week 12 (treated episodes at 30 min post-dose based on home-dosing diary in mITT population)



AEs in $\geq 5\%$ of patients treated with APL during maintenance phase of study 1 and with greater incidence than placebo


	Titration % APL (n = 141)	Maintenance %	
		APL (n = 54)	PBO (n = 55)
Gastrointestinal disorders			
Nausea	21	28	4
Oral/pharyngeal soft tissue swelling	1	15	0
Oral/pharyngeal soft tissue pain and paresthesia	2	13	2
Oral ulceration and stomatitis	2	7	0
Oral mucosal erythema	4	7	4
Vomiting	4	7	0
Dry mouth	1	6	0
Nervous system disorders			
Somnolence	11	13	2
Dizziness	11	9	0
Headache	8	6	0

Olanow CW, et al. *Lancet Neurol.* 2020;19:135-144. Apomorphine sublingual film (Kynmobi™) PI, 2020 (www.kynmobi.com/Kynmobi-Prescribing-Information.pdf).

Advanced Surgical Therapies


Deep-brain stimulation

Stimulation of globus pallidus interna or subthalamic nucleus




Intestinal levodopa infusion

Continuous infusion of levodopa directly into the jejunum




Focused ultrasound

Thalamic ablation for tremor



Mishima T, et al. *J Pers Med.* 2021;11:650. Martinez-Fernandez R, et al. *N Engl J Med.* 2020;383:2501-2513.


Identifying Candidates for Surgical Therapies



Rizek P, et al. *CMAJ*. 2016;188:1157-1165.

Levodopa-Carbidopa Intestinal Gel (LCIG)

- Developed in Sweden in 1990s, LCIG was approved in European Union in 2004 and in US in 2015
- Available in >40 countries worldwide for treatment of advanced levodopa-responsive PD with severe motor fluctuations
- LCIG bypasses stomach and is intended to avoid effects of slowed or delayed gastric emptying
- LCIG is administered directly into small intestine via PEG-J





PEG-J = percutaneous endoscopic gastrostomy with a jejunal extension tube.

Carbidopa-levodopa enteral suspension (Duopa®) PI, 2020 (www.rxabbvie.com/pdf/duopa_pi.pdf). Accessed 8/12/2021. Wirdefeldt K, et al. *CNS Drugs*. 2016;30:381-404.

LCIG: Pivotal Study

Continuous intrajejunal infusion of LCIG for patients with advanced PD:
randomized, controlled, double-blind, double-dummy study



* $P < .05$.

CLIR = carbidopa/levodopa immediate-release.

Modified from Olanow CW, et al. *Lancet Neurol*. 2014;13:141-149.


Deep-Brain Stimulation (DBS)

- Common targets: GPi, STN; rarely VIM thalamus for tremor
- Patient selection is critical
 - Advanced PD with wearing off and dyskinesias or prominent tremor
 - Dyskinesia that is bothersome
 - Younger patients with motor fluctuations within 2 years (onset in <50; may be candidates for earlier DBS)
 - Good levodopa response (exception: tremor dominant)
 - If gait/balance are primary problems, then DBS not likely to be helpful; could help some freezing
 - No significant cognitive impairment
 - May worsen after surgery
 - Neuropsychological testing performed to evaluate
- Management of expectations

GPi = globus pallidus internus; STN = subthalamic nucleus; VIM = ventral intermedius nucleus.

Okun MS. *N Engl J Med*. 2012;367:1529-1538.

Electrode implantation for DBS



Lead for deep-brain stimulation is implanted in either subthalamic nucleus or internal segment of globus pallidus, passing through burr hole in skull. Attached to lead is connecting wire, which is tunneled under skin of scalp and neck to anterior chest wall, where it is connected to impulse generator.


Subthalamic Nucleus (STN): DBS Outcomes

	DBSPD study group ¹	PROGRESS ²	INTREPID ³
# patients	94	234	160 (121 active/39 control)
Study duration	3 months	12 months	3 months
Study design	Prospective, double-blind crossover	Prospective crossover with double-blind primary endpoint	RCT—sham control (3:1)
Age	59.0 (9.6) yrs	61.7 (8.4) yrs	59.9 (8.0) yrs
Disease duration	14.4 yrs	10.2 (7.4) yrs	10.1 (3.6) yrs
ON without troublesome dyskinesia	4.5 hours	4.3 hours	3.74 hours difference from baseline
UPDRS motor meds OFF vs meds OFF/stimulation ON	49% improvement	43% improvement with directional stim at 6 mos	42% improvement with stim
Device	Constant voltage	Constant current	Multiple independent constant-current control
Lead	Non-segmented	Segmented	8-contact, non-segmented

DBSPD = Deep-brain stimulation for Parkinson's disease; meds = medications; stim = stimulation; RCT = randomized controlled trial.

1. Obeso JA, et al. *N Engl J Med*. 2001;345:956-963. 2. Schnitzler A, et al. *Neuromodulation*. 2021;May 27: Epub ahead of print. 3. Vitek J, et al. *Lancet Neurol*. 2020;19:491-501.

The Complete Picture of Parkinson's Disease



NMS = non-motor symptoms; DAWS = dopamine agonist withdrawal syndrome; ICD = impulse control disorders; SIBO = small intestinal bacteria overgrowth.

Todorova A, et al. *Pract Neurol*. 2014;14:310-322.


Multidisciplinary Team for Parkinson's Disease

Members of multidisciplinary team listed by European PD Standards of Care consensus statement and their role in care and management of people with PD^{1,2}

Multidisciplinary team member	Role is to:
General practitioner	Provide day-to-day clinical management
Movement disorder specialist/neurologist	Plan and monitor treatment
Geriatrician	Provide general in- and outpatient management
PD nurse specialist	Manage care and coordinate with hospital and community services
Physiotherapist	Maximize functional ability
Speech and language therapist	Manage difficulties with speech, communication, eating, drinking, and swallowing
Occupational therapist	Advise on measures to retain independence
Nutritionist	Ensure optimal nutrition
Psychologist	Treat depression and other mental health problems
Pharmacists	Ensure supplies of specialty medications
Complementary therapists	Provide massage and relaxation therapies

1. Pedersen SW, et al. *J Multidiscip Healthc.* 2017;10:13-27. 2. EPDA (European Parkinson's Disease Association) standards of care consensus statement. 2012 (www.epda.eu.com/media/1181/epda-consensus-statement-en.pdf). Accessed 8/12/2021.

Once OFF Episodes Emerge, Shared Clinical Decision-Making Can Help Guide Adjustment to Levodopa Regimen and/or Addition of Adjunctive Therapy



Vijjaratnam N, Foltynie T. *Drugs.* 2020;80:775-796. Tanner CM. *Am J Manag Care.* 2020;26(12 suppl):S255-S264.

Goal of Treatment: Continuous “Best-ON”

- Maintain duration of ON
 - Use extended/continuous levodopa formulations and COMT inhibitors
 - Consider MAO-B inhibitors, dopamine agonists, NMDA, and A2A antagonists
- Reduce variability of ON
 - Use non-oral medications, extended release and continuous formulations, and adjunctive medications
 - Utilize on-demand, non-oral therapies for rapid, reliable, and robust response
- Address dose-limiting levodopa-induced dyskinesias, Parkinson’s disease psychosis, neurogenic orthostatic hypotension, and drug-related adverse events
 - Treat when cannot avoid

MAOI = MAO inhibitor; PDP = Parkinson’s disease psychosis; NOH = neurogenic orthostatic hypotension; D-AEs = drug adverse events

Managing OFF Episodes: Shared Decision-Making Should Consider Many Factors

OFF episodes can help guide treatment decision-making

- Type of OFF episodes
- Frequency and severity of OFF episodes
- Timing of OFF episodes
- Impact on daily life

Medication prescribing information should be considered

- Access
- Dosing and route
- Efficacy
- Tolerability and safety
- Clearance and drug-drug interactions

Patient factors can impact treatment decisions

- Comorbidities
- Concomitant medications
- Prior sensitivity to medication changes
- Presence (or absence) of dyskinesia, psychosis, orthostatic hypotension
- Non-motor symptoms

Stocchi F. *Expert Opin Pharmacother.* 2006;7:1399-1407. Olanow CW, et al. *Mov Disord.* 2020;35:1731-1744. Poewe W, Mahlknecht P. *Neurol Clin.* 2020;38:255-267. Pahwa R, Isaacson SH. *J Clin Psychiatry.* 2020;82:SU19004BR2C. Grimes D, et al. *CMAJ.* 2019;191:E989-E1004.

Case Study

Thomas

History

- Thomas is a 62-year-old RH gentleman with Parkinson's for 9 years, beginning with right-hand tremor
 - Works as high school teacher
 - Had grandfather with PD
- Initial treatment with rasagiline 1 mg
- CD/LD 25/100 TID started 7 years ago with robust response
- 5 years ago, 25/100 increased to 1.5/1.5/1 for slowness and occasional tremor

RH = right-handed; TID = three times per day.

Emergence of OFF Episodes

- 3 years ago, end-dose was wearing off 4 hours after each dose
- 25/100 changed to 1.5/1/1.5/1 at 4-hour intervals
- 2 years ago, pramipexole ER was titrated to 1.5 mg QAM and CD/LD was adjusted to 1.5/1/1/1 at 8 am/12 pm/4 pm/8 pm


QAM = every morning.

Current Evaluation

- Evaluation in clinic today, with OFF episodes recurring between some doses
 - Slow in morning until first CD/LD onset
- Exam when ON with no tremor
 - Mild R>L bradykinesia and rigidity
 - Arises from chair without use of arms, and gait brisk with reduced right-arm swing
 - Postural reflexes normal
 - During visit, he develops OFF symptoms with lower voice, reduced facial expression, tremor in his right hand and leg, and use of arms to arise from chair
 - Gait is stooped, slow, with 4-step turns; he takes 2 steps to regain balance when pulled backwards

R>L = right greater than left.

Medication History



How would you manage Thomas?

Management

- Adjusting CD/LD timing was not convenient for him
- Full ON after one tab of 25/100, so did not increase dose
- Increasing pramipexole in past was limited by ankle edema
- Discussed with patient adding COMT inhibitor or nondopaminergic agent and/or use of on-demand treatment
- Patient was hesitant to begin new medication when he was feeling good most of the day
 - Symptoms were only bothersome in the morning
- He opted for the apomorphine sublingual film

Case Study

Patrick

History

- Patrick is a 55-year-old RH gentleman with PD for 6 years, beginning with left-hand tremor
- Former professional golfer, working part-time as golf pro at local course
- Initial treatment with CD/LD 25/100 TID with robust response
- 4 years ago, 25/100 was increased to 1.5/1/1 for "slow-and-stiff" golf swing
 - Then increased to 1.5 TID because he "felt better" with 1.5 tab than with 1 tab of 25/100
 - Fourth dose was added in evening: 1.5/1.5/1.5/1

Emergence of OFF Episodes


- 3 years ago, end dose was wearing off 3.5 hours after each dose, and he switched to CD/LD ER 145 mg 2/2/2/2 at 4-hour intervals
- 2 years ago, OFF episodes occurred 1–2 times daily, usually at end of dose
- Opicapone 50 mg was added Qhs, and inhaled levodopa was also prescribed

Qhs = at every bedtime.

Current Evaluation

- Evaluation in clinic today, with OFF episode almost every morning, lasting for 45–90 minutes
- Other doses sometimes work quickly, but one dose most days is delayed for 30–60 minutes: "I never know when a dose may not work for an hour!"
- Exam when ON with mild R>L bradykinesia
- Arises from chair without use of arms, and gait with reduced right-arm swing and stride
- Postural reflexes normal

Medication History



How would you manage this patient?

Management

- Adjusting CD/LD timing to <4 hours was difficult for him to adhere to
- Increasing CD/LD did not improve OFF episodes and mild dyskinesia emerged
- Discussed with patient adding once-daily dopamine agonist, MAO-B inhibitor, or a nondopaminergic medication, and/or use of on-demand treatment
- Patient was hesitant to begin new daily medication when he was mainly having symptoms in morning or when dose was delayed in onset; most of day he was feeling good
- He opted for inhaled levodopa at end of dose, but sometimes found himself OFF before he used it
- Patient decided to try apomorphine instead for on-demand therapy



Personalizing Treatment for **PARKINSON'S DISEASE:**

*What Can You Do to Manage
OFF EPISODES in Your Patients?*

WHITEBOARD ANIMATIONS

How Patients Experience the 4 Types of Off Episodes: <https://youtu.be/ueRuYAMG0QY>

Mechanism of Action of Therapies for OFF Episodes: <https://youtu.be/5KHxj6jufGY>

Build your own
complimentary
poster for the
office!



Supplement your
Course Learning.
It's fast and easy.



We'll ship it
to you directly
free of charge



Personalizing Treatment for **PARKINSON'S DISEASE:**

*What Can You Do to Manage
OFF EPISODES in Your Patients?*

PLEASE VISIT PDOFFEPISODES.POSTERPROGRAM.COM



Personalizing Treatment for **PARKINSON'S DISEASE:**

*What Can You Do to Manage
OFF EPISODES in Your Patients?*

*For more resources, please visit **pd-thrive.com***

Personalizing Treatment of Parkinson's Disease: What Can You Do to Manage Off Episodes in Your Patients?

TOOLKIT

Off Episodes in Parkinson's Disease

Resource	Web Address
Todorova A, et al. Non-motor Parkinson's: integral to motor Parkinson's, yet often neglected. <i>Pract Neurol.</i> 2014;14:310-322.	https://pubmed.ncbi.nlm.nih.gov/24699931/
Chapuis S, et al. Impact of the motor complications of Parkinson's disease on the quality of life. <i>Mov Disord.</i> 2005;20:224-230.	https://pubmed.ncbi.nlm.nih.gov/15384126/
Onozawa R, et al. The impact of early morning off in Parkinson's disease on patient quality of life and caregiver burden. <i>J Neurol Sci.</i> 2016;364:1-5.	https://pubmed.ncbi.nlm.nih.gov/27084204/
Rizos A, et al. Characterizing motor and non-motor aspects of early-morning off periods in Parkinson's disease: An international multicenter study. <i>Parkinsonism Relat Disord.</i> 2014;20:1231-1235.	https://pubmed.ncbi.nlm.nih.gov/25269446/
Pfeiffer RF, et al. Clinical implications of gastric complications on levodopa treatment in Parkinson's disease. <i>Parkinsonism Relat Disord.</i> 2020;76:63-71.	https://pubmed.ncbi.nlm.nih.gov/32461054/
van Kessel SP, et al. Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson's disease. <i>Nat Commun.</i> 2019;10:310.	https://pubmed.ncbi.nlm.nih.gov/30659181/
Hauser RA, et al. Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson's disease. <i>Neuropsychiatr Dis Treat.</i> 2018;14:839-842.	https://pubmed.ncbi.nlm.nih.gov/29606877/

On-Demand Therapies

Resource	Web Address
Olanow CW, et al. On-demand therapy for OFF episodes in Parkinson's disease [published online ahead of print, 2021 Aug 7]. <i>Mov Disord.</i> 2021;10.1002/mds.28726.	https://pubmed.ncbi.nlm.nih.gov/34363424/
Olanow CW, et al. Apomorphine sublingual film for off episodes in Parkinson's disease: A randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Neurol.</i> 2020;19:135-144.	https://pubmed.ncbi.nlm.nih.gov/31818699/

Hauser RA, et al. Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease. <i>Mov Disord.</i> 2016;31:1366-1372.	https://pubmed.ncbi.nlm.nih.gov/27430123/
Lipp MM, et al. Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson's disease. <i>Sci Transl Med.</i> 2016;8:360ra136.	https://pubmed.ncbi.nlm.nih.gov/27733560/
Safirstein BE, et al. Pharmacokinetics of inhaled levodopa administered with oral carbidopa in the fed state in patients with Parkinson's disease. <i>Clin Ther.</i> 2020;42:1034-1046.	https://pubmed.ncbi.nlm.nih.gov/32482490/
LeWitt PA, et al. A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease. <i>Mov Disord.</i> 2016;31:1356-1365.	https://pubmed.ncbi.nlm.nih.gov/27090868/
LeWitt PA, et al. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: A randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Neurol.</i> 2019;18:145-154.	https://pubmed.ncbi.nlm.nih.gov/30663606/
Pfeiffer RF, et al. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease. <i>Parkinsonism Relat Disord.</i> 2007;13:93-100.	https://pubmed.ncbi.nlm.nih.gov/17055329/
Pahwa R, et al. Subcutaneous apomorphine in patients with advanced Parkinson's disease: A dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose. <i>J Neurol Sci.</i> 2007;258:137-143.	https://pubmed.ncbi.nlm.nih.gov/17466338/
Isaacson S, et al. Apomorphine subcutaneous injection for the management of morning akinesia in Parkinson's disease. <i>Mov Disord Clin Pract.</i> 2017;4:78-83.	https://pubmed.ncbi.nlm.nih.gov/28239615/

Adjunctive Therapies

Resource	Web Address
Kalia LV, et al. Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials. <i>Mov Disord.</i> 2013;28:131-144.	https://pubmed.ncbi.nlm.nih.gov/23225267/
Lees AJ, et al. Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations: A randomized clinical trial. <i>JAMA Neurol.</i> 2017;74:197-206.	https://pubmed.ncbi.nlm.nih.gov/28027332/

Poewe W, et al. Extended-release pramipexole in early Parkinson disease: A 33-week randomized controlled trial. <i>Neurology</i> . 2011;77:758-766.	https://pubmed.ncbi.nlm.nih.gov/21832218/
Pahwa R, et al. Ropinirole 24-hour prolonged release: Randomized, controlled study in advanced Parkinson disease. <i>Neurology</i> . 2007;68:1108-1115.	https://pubmed.ncbi.nlm.nih.gov/17404192/
Müller T. Safinamide: An add-on treatment for managing Parkinson's disease. <i>Clin Pharmacol</i> . 2018;10:31-41.	https://pubmed.ncbi.nlm.nih.gov/29670409/
Pahwa R, et al. ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson disease (EASE LID study): A randomized clinical trial. <i>JAMA Neurol</i> . 2017;74:941-949.	https://pubmed.ncbi.nlm.nih.gov/28604926/